Pfizer Inc. (PFE) to Issue Quarterly Dividend of $0.43 on December 1st

Pfizer Inc. (NYSE:PFE) announced a quarterly dividend on Thursday, October 9th, RTT News reports. Investors of record on Friday, November 7th will be given a dividend of 0.43 per share by the biopharmaceutical company on Monday, December 1st. This represents a c) annualized dividend and a yield of 7.1%. The ex-dividend date is Friday, November 7th.

Pfizer has raised its dividend by an average of 0.0%per year over the last three years and has increased its dividend every year for the last 16 years. Pfizer has a dividend payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Pfizer to earn $3.03 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 56.8%.

Pfizer Stock Down 1.4%

NYSE:PFE opened at $24.32 on Wednesday. The firm’s 50 day simple moving average is $24.75 and its 200 day simple moving average is $24.33. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer has a one year low of $20.92 and a one year high of $28.00. The company has a market cap of $138.24 billion, a PE ratio of 12.93, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on PFE shares. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.24.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.